TransCode Therapeutics Welcomes Jack E. Stover to its Board of Directors

TransCode Therapeutics Welcomes a New Leader to the Board

TransCode Therapeutics, Inc., a pioneering clinical stage company focused on immuno-oncology and RNA therapies for high-risk cancer patients, has announced the addition of Jack E. Stover to its Board of Directors. This strategic move is poised to enhance the company’s leadership and direction as it navigates the complex realm of cancer treatment.

Experience and Expertise of Jack E. Stover

Jack E. Stover brings with him over three decades of executive leadership in the life sciences and pharmaceutical industry. His background spans various sectors including drug development, diagnostics, specialty pharmaceuticals, and capital formation. This extensive experience positions him as a valuable addition to TransCode, especially given the company’s ambitions to advance its groundbreaking pipeline focused on RNA and immuno-oncology therapies.

“Welcoming Jack to our Board is an exciting development for TransCode Therapeutics,” said Philippe P. Calais, the CEO of the company. “His unique operational, financial, and strategic acumen, combined with a proven track record of facilitating transformative growth, will undoubtedly be an asset as we strive to expand our capabilities and bring our innovative treatments to market.”

Stover's current role includes serving as Chairman of the Board at Traws Pharma Inc., a specialty pharmaceutical company that concentrates on anti-virals and oncology. His past accomplishments also include leading Traws through a merger with Onconova Therapeutics Inc. In addition, he has significant experience as a Director and Chairman of Audit Committees for various companies, including Onconova since 2016.

From March 2021 to July 2025, Stover held the positions of CEO and Director for NorthView Acquisition Corp, a special purpose acquisition corporation. His previous experience as President, CEO, and Director at Interpace Biosciences, Inc. demonstrates his capability in navigating the intricacies of oncology molecular diagnostics. Under his leadership, Interpace completed several successful financing rounds and acquired Cancer Genetics.

Looking Forward

Stover expressed enthusiasm about joining TransCode, stating, “I am pleased to join the Board at a pivotal time for the company. I look forward to contributing to our mission of delivering innovative solutions for patients battling cancer.” His vision aligns seamlessly with TransCode’s overarching goal of providing cutting-edge therapies that could reshape treatment paradigms in oncology.

With the addition of Stover, TransCode is poised to leverage his insights and connections in the industry to propel its research and development efforts further. The board will benefit from his knowledge in navigating the regulatory complexities and market dynamics pertinent to the biotech sector, which are crucial for the success of any company operating at the forefront of medical innovation.

Pharmaceutical development is a challenging journey laden with risks—ranging from clinical trial results not meeting expectations to financial uncertainties and the imperative for continuous funding. Stover’s extensive experience can help TransCode mitigate these potential challenges while seizing new opportunities in drug discovery and therapeutic advancements.

Conclusion

The appointment of Jack E. Stover to the Board of Directors at TransCode Therapeutics marks a significant step as the company positions itself for future growth. His extensive background in life sciences and strategic insights will support TransCode’s mission of creating a cancer-free future. This development is expected to enhance the company’s efforts in delivering innovative cancer therapies and building a robust pipeline that can face the increasing challenges in the oncology healthcare landscape.